SARS-CoV-2肺炎重症监护室幸存者一年前瞻性随访结果
该单中心、前瞻性、观察性研究纳入85例SARS-CoV-2肺炎ICU幸存者,在症状出现后3、6、12个月进行系统评估,包括体格检查、肺功能、胸部CT、标准化六分钟步行试验及连续血氧监测、夜间家庭呼吸多导图和生活质量问卷。主要终点为12个月时DLCO所测肺泡-毛细血管屏障功能较参考值的改变。多数患者在3、6、12个月各时间点DLCO改善;3个月时77例(96.3%)胸部CT异常,12个月比例相同但模式已改变。
要点
- 85例SARS-CoV-2肺炎ICU幸存者中位年龄68.4岁(IQR 60.1-72.9),78.8%为男性。
- 中位住院时间44天(IQR 20-60),其中ICU住院17天(IQR 11-26)。
- 肺功能检查在症状出现后3个月(n=85)、6个月(n=80)、12个月(n=73)完成,多数患者各时间点DLCO改善。
- 3个月时77例(96.3%)胸部CT异常,12个月异常比例相同但模式已改变。
- DLCO恢复正常者除1例外后续均未再恶化。
适用人群与场景
- SARS-CoV-2肺炎存活并入住ICU的患者,前瞻性识别队列。
- 在症状出现后3、6、12个月进行随访评估。
研究设计与关键结果
- 研究类型:单中心、前瞻性、观察性研究,纳入85例SARS-CoV-2肺炎ICU幸存者。
- 中位年龄68.4岁(IQR 60.1-72.9岁),78.8%为男性。
- 中位住院时间44天(IQR 20-60),其中ICU住院17天(IQR 11-26)。
- 主要终点:12个月时DLCO所测肺泡-毛细血管屏障功能较参考值的改变。
- 肺功能检查完成例数:3个月n=85,6个月n=80,12个月n=73。
- 多数患者在3、6、12个月各时间点DLCO改善。
- DLCO恢复正常的所有患者中,除1例外后续未再恶化。
- 3个月时77例(96.3%)胸部CT异常,12个月异常比例相同但模式已改变。
证据类型、等级与局限
- 证据类型:单中心、前瞻性、观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者报告多数SARS-CoV-2肺炎ICU幸存者在症状出现后3、6、12个月各时间点DLCO改善。
- 作者报告3个月时96.3%患者胸部CT异常,12个月异常比例相同但模式已改变。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Survivors of viral ARDS are at risk of long-term physical, functional and neuropsychological complications resulting from the lung injury itself, but also from potential multiorgan dysfunction, and the long stay in the intensive care unit (ICU). Recovery profiles after severe SARS-CoV-2 pneumonia in intensive care unit survivors have yet to be clearly defined.
MATERIAL AND METHODS: The goal of this single-center, prospective, observational study was to systematically evaluate pulmonary and extrapulmonary function at 12 months after a stay in the ICU, in a prospectively identified cohort of patients who survived SARS-CoV-2 pneumonia. Eligible patients were assessed at 3, 6 and 12 months after onset of SARS-CoV-2. Patients underwent physical examination, pulmonary function testing, chest computed tomography (CT) scan, a standardized six-minute walk test with continuous oximetry, overnight home respiratory polygraphy and have completed quality of life questionnaire. The primary endpoint was alteration of the alveolar-capillary barrier compared to reference values as measured by DLCO, at 12 months after onset of SARS-CoV-2 symptoms.
RESULTS: In total, 85 patients (median age 68.4 years, (interquartile range [IQR] = 60.1-72.9 years), 78.8% male) participated in the trial. The median length of hospital stay was 44 days (IQR: 20-60) including 17 days in ICU (IQR: 11-26). Pulmonary function tests were completed at 3 months (n = 85), 6 months (n = 80), and 12 months (n = 73) after onset of symptoms. Most patients showed an improvement in DLCO at each timepoint (3, 6, and 12 months). All patients who normalized their DLCO did not subsequently deteriorate, except one. Chest CT scans were abnormal in 77 patients (96.3%) at 3 months and although the proportion was the same at 12 months, but patterns have changed.
CONCLUSION: We report the results of a comprehensive evaluation of 85 patients admitted to the ICU for SARS-CoV-2, at one-year follow-up after symptom onset. We show that most patients had an improvement in DLCO at each timepoint.
TRIAL REGISTRATION: Clinical trial registration number: NCT04519320.
参考来源
- Eberst G, Claudé F, Laurent L, et al. Result of one-year, prospective follow-up of intensive care unit survivors after SARS-CoV-2 pneumonia. Ann Intensive Care. 2022. PMID: 35262794. doi:10.1186/s13613-022-00997-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。